Pharming Group N.V.
PHGUF
Get informed when a big investor buys or sells
+ FollowMarket Cap$690.09M
Close$
Share Statistics
| Market cap | $690.09 Million |
|---|---|
| Enterprise Value | $645.10 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 3.13% |
|---|---|
| Return on Assets | 1.81% |
| Return on Invested Capital | 1662.21% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.84 |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | 76 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$99.52 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$103.54 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Pharming Group N.V.
407 employees
CEO: Sijmen de Vries Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, ...